Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE MESYLATE versus SEREVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE MESYLATE versus SEREVENT.
ISOETHARINE MESYLATE vs SEREVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP in bronchial smooth muscle, leading to bronchodilation.
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Inhalation: 1-2 inhalations (0.34 mg per actuation) via metered-dose inhaler every 4-6 hours as needed; or 0.25-0.5 mL of 1% solution diluted in 2-3 mL of normal saline via nebulizer every 4-6 hours.
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5–5 hours in adults after inhalation; may be prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor.
Primarily renal excretion of unchanged drug and metabolites (sulfate and glucuronide conjugates); approximately 40-50% excreted renally as unchanged drug within 24 hours, with the remainder as metabolites. Biliary/fecal excretion is minimal (<5%).
Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist